Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.

The Journal of clinical investigation - 1 Aug 2022

Yan Dan, Huelse Justus M, Kireev Dmitri, Tan Zikang, Chen Luxiao, Goyal Subir, Wang Xiaodong, Frye Stephen V, Behera Madhusmita, Schneider Frank, Ramalingam Suresh S, Owonikoko Taofeek, Earp H Shelton, DeRyckere Deborah, Graham Douglas K

Abstract excerpt

Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 promoted downstream oncogenic signaling in EGFR-mutated (EGFRMT) NSCLC cells treated with OSI, suggesting a role for MERTK activation in OSI resistance. Indeed, treatment with MRX-2843, a first-in-class MERTK kinase inhibitor, resensitized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to c-Mer Tyrosine Kinase

Share to Drug Resistance, Neoplasm

Share to Indoles

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35708914
DOI: 10.1172/JCI150517
PMCID: PMC9337831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.PMID 35708914Read ↗

Co-targeting MERTK and EGFR with a Bispecific Antibody Overcomes Drug Resistance Across Mutations in Exons 19, 20, and 21Semantic proximity Read ↗

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancerSemantic proximity Read ↗

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.Semantic proximity Read ↗

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read ↗

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.Semantic proximity Read ↗

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read ↗

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC.Semantic proximity Read ↗

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.Semantic proximity Read ↗

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.Semantic proximity Read ↗

MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.